Business Description
RxSight Inc
NAICS : 339112
SIC : 3845
ISIN : US78349D1072
Total Employee Number:
461Description
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 19.74 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.24 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.19 | |||||
Beneish M-Score | -1.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 22.9 | |||||
3-Year EBITDA Growth Rate | 25.3 | |||||
3-Year EPS without NRI Growth Rate | 55.2 | |||||
3-Year FCF Growth Rate | 40.2 | |||||
3-Year Book Growth Rate | 28.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.32 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.98 | |||||
9-Day RSI | 43.72 | |||||
14-Day RSI | 48.66 | |||||
3-1 Month Momentum % | 22.55 | |||||
6-1 Month Momentum % | -21.19 | |||||
12-1 Month Momentum % | -26.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.07 | |||||
Quick Ratio | 3.61 | |||||
Cash Ratio | 2.6 | |||||
Days Inventory | 400.64 | |||||
Days Sales Outstanding | 66.69 | |||||
Days Payable | 64.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.4 | |||||
Shareholder Yield % | -0.43 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.5 | |||||
Operating Margin % | -43.2 | |||||
Net Margin % | -36.8 | |||||
EBITDA Margin % | -33.93 | |||||
FCF Margin % | -21.29 | |||||
OCF Margin % | -17.82 | |||||
ROE % | -17.26 | |||||
ROA % | -14.8 | |||||
ROIC % | -71.97 | |||||
3-Year ROIIC % | 40.8 | |||||
ROC (Joel Greenblatt) % | -90.42 | |||||
ROCE % | -16.61 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 16.8 | |||||
PS Ratio | 2.06 | |||||
PB Ratio | 1.01 | |||||
Price-to-Tangible-Book | 1.01 | |||||
EV-to-EBIT | -1.43 | |||||
EV-to-Forward-EBIT | 397.26 | |||||
EV-to-EBITDA | -1.55 | |||||
EV-to-Forward-EBITDA | 59.11 | |||||
EV-to-Revenue | 0.52 | |||||
EV-to-Forward-Revenue | 0.71 | |||||
EV-to-FCF | -2.46 | |||||
Price-to-GF-Value | 0.24 | |||||
| Price-to-Net-Current-Asset-Value | 1.11 | |||||
| Price-to-Net-Cash | 2.22 | |||||
Earnings Yield (Greenblatt) % | -69.93 | |||||
FCF Yield % | -10.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RXST
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RxSight Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 127.582 | ||
| EPS (TTM) ($) | -1.13 | ||
| Beta | 2.239 | ||
| 3-Year Sharpe Ratio | -0.37 | ||
| 3-Year Sortino Ratio | -0.5 | ||
| Volatility % | 64.12 | ||
| 14-Day RSI | 48.66 | ||
| 14-Day ATR ($) | 0.410819 | ||
| 20-Day SMA ($) | 6.64425 | ||
| 12-1 Month Momentum % | -26.21 | ||
| 52-Week Range ($) | 4.48 - 13.22 | ||
| Shares Outstanding (Mil) | 41.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RxSight Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RxSight Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-25 16:30 | In 172 days | ||
| Annual report for 2026 | 2027-02-25 | In 171 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 171 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 60 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 59 days | ||
| the Wells Fargo Healthcare Conference | 2026-09-09 09:30 | In 3 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 6.25 (-0.48%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 6.25 (-0.48%) | ||
| General meeting for 2026 | 2026-06-16 08:00 | 4.79 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-26 10:00 | 6.09 (-4.47%) |
Show
Entries
RxSight Inc Frequently Asked Questions
What is RxSight Inc(RXST)'s stock price today?
The current price of RXST is $6.38. The 52 week high of RXST is $13.22 and 52 week low is $4.48.
When is next earnings date of RxSight Inc(RXST)?
The next earnings date of RxSight Inc(RXST) is 2026-11-05 Est..
Does RxSight Inc(RXST) pay dividends? If so, how much?
RxSight Inc(RXST) does not pay dividend.
Guru Commentaries on NAS:RXST
Rodrigo Benedetti
Bullish
2025 Q2
What the manager wrote
RxSight's Light Adjustable Lens (LAL) system represents a significant innovation in the premium intraocular lens market, allowing for precise, non-invasive post-surgical customization using UV light. This technology not only enhances visual outcomes for patients but also improves profitability for surgeons by reducing reliance on preoperative measurements. The LAL outperforms conventional IOLs in uncorrected vision and minimizes common drawbacks like glare and halos. With a current market share of 10%, there is potential for growth as the product's unique advantages become more recognized, possibly increasing penetration rates significantly.
Press Release
Articles on RxSight Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers